Low Float (Nasdaq: SHPH) Climbs Monday's Watchlist Behind 5 Critical Potential Catalysts

In targeted cancer therapy, one specialty pharma player

*Sponsored Low Float (Nasdaq: SHPH) Climbs Monday's Watchlist Behind 5 Critical Potential Catalysts November 2nd Greetings, Friend! In targeted cancer therapy, one specialty pharma player is gaining notice for a novel take on boosting radiation’s impact. Its strategy centers on finely tuned drug combinations that heighten tumor sensitivity yet spare healthy cells, setting new expectations for treatment results. Preliminary data point to promising gains in precision across multiple cancers. Backed by a focused research team and rising clinical traction, this discreet innovator could soon shift how radiation-based medicine is practiced. With fewer than 1Mn shares in its float creating an environment for strong volatility potential, multiple oversold leaning technicals, and a major acquisition nearing completion, this overlooked Nasdaq profile may not stay quiet for much longer: Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Shuttle Pharmaceuticals: Pursuing a Cure for Cancer Shuttle Pharmaceuticals is pioneering therapies to help boost cancer cure rates, extend survival, and improve patient quality of life. Transforming Radiation Therapy Outcomes The company develops treatments that target malignant cells while preserving healthy tissue and engaging the body’s immune system. Its goal is to enhance radiation therapy (RT) effectiveness and reduce side effects. Through proprietary drug discovery and diagnostic platforms, Shuttle is driving new standards in combination cancer treatment. Powering a New Era in RT Radiation therapy is integral to cancer care—over half of U.S. cancer patients receive it during treatment. Shuttle’s drug candidates make cancer cells more radiation-sensitive by triggering DNA damage response pathways while shielding normal tissue. Its lead drug, Ropidoxuridine, is a first-in-class oral halogenated pyrimidine that greatly amplifies RT sensitivity. Innovation Through a Robust Platform Shuttle’s platform has produced patented histone deacetylase (HDAC) inhibitors that modulate radiation’s effects on cancer cells. Academic partnerships have also yielded exclusive diagnostic technologies for managing prostate cancer. The company’s pipeline includes a Phase II clinical candidate (Ropidoxuridine), three preclinical HDAC inhibitors, and a blood-based prostate cancer test in development. Redefining Diagnostic Precision Recognizing variation in prostate tumor behavior, Shuttle is developing a predictive biomarker test to evaluate treatment risk, inform decisions, and guide post-therapy care for patients considering elective radiation therapy. Ropidoxuridine Ropidoxuridine, Shuttle’s lead asset, is a radiation sensitizer under Phase II evaluation for glioblastoma, an aggressive brain cancer. It holds FDA Orphan Drug Designation, offering potential exclusivity post-approval. The compound integrates into the DNA of rapidly dividing cancer cells, intensifying their vulnerability to radiation by forming reactive species that cause fatal DNA breaks. Meeting an Urgent Therapeutic Demand Roughly 800,000 U.S. cancer patients receive radiation annually, half with curative intent. Shuttle’s Ropidoxuridine trial represents a major step toward improving outcomes for more than 400,000 patients each year seeking curative radiation therapy. HDAC Inhibitors and Dual Functional Design HDAC inhibitors influence gene expression by altering chromatin structure—restoring tumor suppressor function through an epigenetic pathway central to modern oncology. Shuttle’s research emphasizes dual-action molecules that heighten tumor sensitivity, protect normal tissue, and stimulate immune engagement. The company holds over 20 HDAC inhibitor patents across North America and Europe. Expanding Precision Oncology Three core candidates are under development for solid tumors: SP-2-225: A Class II (HDAC6)-selective inhibitor enhancing antigen presentation. SP-1-303: A Class I inhibitor targeting ER-positive cancers. SP-1-161: An ATM gene activator with applications in radiobiology. Therapeutics Pipeline Diagnostics PC-RAD Test is a predictive blood test of therapeutic outcomes to RT for organ-confined prostate cancers. PSMA-B ligand is a theranostic molecule for diagnosis and therapy of metastatic prostate cancers. Diagnostics Pipeline Find Sources And More: SHPH Website. SHPH Presentation. ----- 5 Potential Catalysts Put (Nasdaq: SHPH) On Monday's Radar #1. SHPH Is Being Reported As A Low Float Profile Meaning Volatility Potential Could Be Significantly Heightened. SHPH’s low float of approximately 987.08k shares may create conditions for heightened volatility due to its limited supply. #2. A Potential Reversal/Bounce Could Be Right Around The Corner. At close on Friday, Barchart was reporting SHPH to have a 9-Day Relative Strength Index (RSI) below 29% and a 14-Day RSI below 36%. On top of that a 14-Day Raw Stochastic of 5.16% may also suggest a potential reversal may be right around the corner. #3. Shuttle Pharmaceuticals Could Expand Capabilities Through A Strategic AI Platform Acquisition. Shuttle Pharmaceuticals Holdings signed a binding term sheet to acquire Canadian AI company Molecule for $10Mn in cash and st-ock. The acquisition will strengthen Shuttle’s drug discovery and development capabilities through Molecule’s advanced molecular modeling and predictive analytics platform. CEO Chris Cooper stated that the move supports Shuttle’s mission to advance precision radiotherapy solutions. The deal, pending due diligence and final agreements, marks a major step in expanding Shuttle’s technological foundation and accelerating innovation in cancer treatment. #4. Shuttle Pharma Provides Second Quarter 2025 Corporate Update. The company recently provided a key corporate update. Here are some important details: Patient enrollment in the Company’s Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma reached 63% in the initial randomized portion of the trial. 72% of the enrolled patients have completed all seven cycles. Ropidoxuridine is being reported by treatment sites as well tolerated. Ended the quarter with $4.8Mn in cash following the closing of a private placement pursuant to a securities purchase agreement with an accredited in-vest-or for aggregate gross proceeds of $4.25Mn in June 2025. Completed a reverse st-ock split in June 2025 as part of strategic Nasdaq compliance initiative. Appointed George Scorsis as the Chairman of the Board of Directors and appointed Christopher Cooper, our current Interim Chief Executive Officer to our Board of Directors. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth. Mr. Cooper has over 27 years of management and finance experience. #5. SHPH Acheives Multiple Partnerships For Cancer Diagnostics And Therapeutics Clinical Trial Development Support. The company maintains strategic agreements and contracts with academic institutions to access intellectual property, core facilities, and contracting relationships essential to its programs. University of California, San Francisco (UCSF) Shuttle entered a sponsored research agreement with UCSF to advance pre-clinical development of Shuttle Diagnostics, Inc.’s PSMA ligand as a potential theranostic molecule, led by principal investigator Robert Flavell, M.D., Ph.D.. The work aims to develop radiosynthetic methods for producing the [18F]FPA-ACUPA probe, investigate cellular binding in prostate cancer cell lines, and assess diagnostic potential across prostate cancer phenotypes; Shuttle holds an exclusive license to PSMA-B intellectual property and has filed a U.S. patent application. Georgetown University Georgetown University’s Lombardi Comprehensive Cancer Center supports discovery and development of cancer diagnostics and therapeutics, with Shuttle subcontracting SBIR-funded clinical work to establish cancer cell lines from African-American patients and develop predictive biomarkers for radiation late-effects sensitivity. Brown University Shuttle received an NIH SBIR contract for a Phase I clinical trial with Brown University at Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in advanced gastrointestinal cancers, with NCI approving the protocol and providing drug and clinical data management support. The completed Phase I trial supports advancing Ropidoxuridine to Phase II trials in brain tumors, sarcomas, and other tumors. University of Virginia The University of Virginia, which developed “Atomic Radiation” intellectual property, collaborates with Shuttle scientists on sensitizers for use with proton radiation therapy. George Washington Cancer Center Collaborations between the Villagra lab at George Washington University and Shuttle’s lab led to an October 2020 AACR presentation on “Immune-mediated Tumor Growth Inhibition by Selective HDAC6 Inhibitor SP-2-225,” with Dr. Villagra serving as a Shuttle scientific advisor since 2017. A material transfer agreement supports testing HDAC inhibitor effects in immune model systems. TCG GreenChem TCG GreenChem Inc., part of the TCG Group with presence in the United States, India, and Japan, is a CRAMS company affiliated with TCG Lifesciences Pvt. Ltd. and joined Shuttle’s leadership team in 2020 to manufacture drug product for proposed clinical trials. TCG GreenChem has also been engaged to manufacture Ropidoxuridine and perform process R&D and optimization to support Shuttle’s clinical programs. ----- We're officially kicking-off coverage Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH). Keep your eyes peeled for updates coming soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 11/02/2025 and ending on 11/03/2025 to publicly disseminate information about (SHPH:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (SHPH:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/shph-7e6wx/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice